Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Yang Website

James C. Yang, M.D.

Selected Publications

1)  Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science. 344: 641-5, 2014.
[Journal]
2)  Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U.
Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial.
Ann. Surg. Oncol. [Epub ahead of print], 2014.
[Journal]
3)  Yang JC, Sherry RM, Rosenberg SA.
Melanoma: Why is sentinel lymph node biopsy "standard of care" for melanoma?.
Nat Rev Clin Oncol. 11: 245-6, 2014.
[Journal]
4)  Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.
J. Clin. Invest. 124: 2246-59, 2014.
[Journal]
5)  Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC.
Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.
Cancer. 120: 1426-32, 2014.
[Journal]
6)  Kwong ML, Neyns B, Yang JC.
Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy.
Clin. Cancer Res. 19: 5292-9, 2013.
[Journal]
7)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
[Journal]
8)  Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA.
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
Blood. 122: 1399-410, 2013.
[Journal]
9)  Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF.
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.
J. Immunol. 190: 6034-42, 2013.
[Journal]
10)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma.
J. Clin. Oncol. 31: 2152-9, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/21/2014.